You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CLINICAL TRIALS PROFILE FOR INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for insulin aspart protamine recombinant; insulin aspart recombinant

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00795600 ↗ Comparison of the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After Insulin Treatment Completed Novo Nordisk A/S Phase 4 2009-04-01 This trial is conducted in Europe. The aim of this clinical trial is to compare the change in trunk fat mass, assessed by Double Energy X-ray Absorptiometry (DEXA) after 26 weeks of treatment with insulin detemir or insulin NPH (Neutral Protamine Hagedorn) (both combined with insulin aspart at the main meals) in overweight and obese subjects with type 2 diabetes.
NCT00821795 ↗ Veterans Inpatient Insulin Study and Transition to Outpatient Therapy Completed Novo Nordisk A/S Phase 4 2009-03-11 Volunteers are being invited to take part in a research study about insulin therapy of diabetes. They are being invited to take part in this research study because they have diabetes and have an illness requiring hospitalization. If they volunteer to take part in this study, they will be one of about 120 people to do so. The investigators hope to answer the following research questions: - To show that insulin aspart protamine 70/30 mix taken twice daily is as good as insulin NPH/Reg 70/30 mix taken twice a day for treatment of diabetes after discharge from the hospital. - To show how safe the two medicines are (insulin aspart 70/30 mix vs. insulin NPH/Reg 70/30 mix) and how well they work for the treatment of diabetes when transitioning from inpatient therapy to outpatient care.
NCT00821795 ↗ Veterans Inpatient Insulin Study and Transition to Outpatient Therapy Completed Dennis G. Karounos, M.D. Phase 4 2009-03-11 Volunteers are being invited to take part in a research study about insulin therapy of diabetes. They are being invited to take part in this research study because they have diabetes and have an illness requiring hospitalization. If they volunteer to take part in this study, they will be one of about 120 people to do so. The investigators hope to answer the following research questions: - To show that insulin aspart protamine 70/30 mix taken twice daily is as good as insulin NPH/Reg 70/30 mix taken twice a day for treatment of diabetes after discharge from the hospital. - To show how safe the two medicines are (insulin aspart 70/30 mix vs. insulin NPH/Reg 70/30 mix) and how well they work for the treatment of diabetes when transitioning from inpatient therapy to outpatient care.
NCT00965549 ↗ Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients Completed Sanofi Phase 4 2009-07-01 The primary objective is to demonstrate the non-inferiority at six months of a basal plus one insulin regimen (Lantus plus one injection of Apidra) compared with a biphasic insulin regimen (NovoMix 30) at controlling glycosylated haemoglobin (HbA1c) in type 2 diabetes. The secondary objective are: - To compare the proportion of patients in each treatment group reaching HbA1c target (< 7%) at the end of the treatment period - To compare the rates of hypoglycaemia (total, severe, nocturnal) - To compare the change in body weight from visit 10 to visit 24 - To compare the change in diabetes specific quality of life and other patient reported outcomes from visit 10 to visit 24 - Diabetes Treatment Satisfaction Questionnaire - status and change (DTSQs+c) - Audit of Diabetes-Dependent Quality of Life (ADDQoL) questionnaire - Insulin Treatment Satisfaction Questionnaire (ITSQ) - EuroQoL 5 Dimensions (EQ5D) questionnaire - To record the change in the daily dose of insulin from visit 2 to visit 10 and visit 10 to visit 24
NCT01212913 ↗ Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM) Completed Sanofi Phase 4 2010-08-01 Primary Objective: To demonstrate the non-inferiority of hemoglobin A1c (HbA1c) control at six months between the basal plus one and the biphasic insulin regimen. Secondary Objective: To demonstrate favorable outcome for basal plus over biphasic insulin when it comes to comparing when both hemoglobin A1c (HbA1c) target goal achievement and non-hypoglycemic event is taken into account.
NCT01648218 ↗ Insulin Therapy for Post-transplant Glucocorticoid Induced Hyperglycemia Terminated Vancouver General Hospital Phase 4 2012-08-01 No consensus guidelines exist for management of post-transplant glucocorticoid induced hyperglycemia, but most published reviews recommend insulin as first line therapy. A variety of insulin regimens have been proposed, including mealtime short-acting regular or analog insulin, once daily neutral protamine hagedorn (NPH) insulin, pre-mixed insulin, or basal insulin alone such as glargine or detemir. However, no randomized trial has ever examined different insulin regimens to determine which most effectively controls post-transplant steroid-induced hyperglycemia. Consequently, the proposed study intends to examine three commonly used insulin regimens used for managing post-transplant once-daily glucocorticoid-induced hyperglycemia to determine which is most effective: - Group 1: Intermediate-acting (NPH) insulin at breakfast - Group 2: Short-acting insulin (regular or aspart) before meals - Group 3: Insulin glargine at breakfast Question/Hypothesis: Among three commonly used insulin regimens, which is most effective for managing post-transplant once-daily glucocorticoid-induced hyperglycemia?
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for insulin aspart protamine recombinant; insulin aspart recombinant

Condition Name

Condition Name for insulin aspart protamine recombinant; insulin aspart recombinant
Intervention Trials
Diabetes Mellitus, Type 2 4
Diabetes 2
Type 2 Diabetes Mellitus 1
Hyperglycemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for insulin aspart protamine recombinant; insulin aspart recombinant
Intervention Trials
Diabetes Mellitus, Type 2 5
Diabetes Mellitus 5
Hyperglycemia 2
Stroke 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for insulin aspart protamine recombinant; insulin aspart recombinant

Trials by Country

Trials by Country for insulin aspart protamine recombinant; insulin aspart recombinant
Location Trials
Japan 1
Australia 1
Canada 1
United States 1
Korea, Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for insulin aspart protamine recombinant; insulin aspart recombinant
Location Trials
Kentucky 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for insulin aspart protamine recombinant; insulin aspart recombinant

Clinical Trial Phase

Clinical Trial Phase for insulin aspart protamine recombinant; insulin aspart recombinant
Clinical Trial Phase Trials
Phase 4 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for insulin aspart protamine recombinant; insulin aspart recombinant
Clinical Trial Phase Trials
Completed 6
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for insulin aspart protamine recombinant; insulin aspart recombinant

Sponsor Name

Sponsor Name for insulin aspart protamine recombinant; insulin aspart recombinant
Sponsor Trials
Novo Nordisk A/S 3
Sanofi 2
Dennis G. Karounos, M.D. 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for insulin aspart protamine recombinant; insulin aspart recombinant
Sponsor Trials
Industry 5
Other 2
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.